NSE:GLAND
Gland Pharma Limited · NSE · Healthcare · INR · FY for 2026
Figures on this page computed 2026-11-07 18:24 UTC
Last close
n/aINR
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
50.8xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
- Computed from the filing for 2026
11.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
16.0%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
11.5%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
0.03Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
0.6%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
Price is the furthest below its sector's middle: 0.17 against 0.36 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2026
- Sales1.74x
Its own average over 10 years, 36.98B.
- Profit1.38x
Its own average over 10 years, 7.45B.
- Free cash flow2.00x
Its own average over 10 years, 3.70B.
- Debt2.81x
Its own average over 10 years, 1.01B.
- Pricen/a
Its own average over 0 years. Market data
Debt is furthest from its own average, at 2.81 times.
The filed years, as a table
10Each line is 100 at 2017-03-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2017-03-31 | 100.0 | 100.0 | 100.0 |
| 2018-03-31 | 109.5 | 77.6 | 100.0 |
| 2019-03-31 | 138.2 | 109.2 | 100.0 |
| 2020-03-31 | 178.0 | 186.8 | 100.0 |
| 2021-03-31 | 234.1 | 241.0 | 102.1 |
| 2022-03-31 | 297.5 | 292.9 | 106.2 |
| 2023-03-31 | 245.0 | 188.8 | 106.3 |
| 2024-03-31 | 383.0 | 186.7 | 106.3 |
| 2025-03-31 | 379.7 | 168.8 | 106.3 |
| 2026-03-31 | 434.7 | 248.3 | 106.5 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- INR
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- INR
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- INR
Figures behind the shape
Growth
13.2%faster is higher, placed against 4,950 companies as of 2026-11-06
Five-year revenue growth rate13.2%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
Five-year EPS growth rate-0.2%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
One-year change in net income47.1%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
Returns on capital
11.6%higher is higher, placed against 5,089 companies as of 2026-11-06
Return on invested capital11.6%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
Return on equity9.9%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
Return on assets8.2%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
Margins
30.1%wider is higher, placed against 3,412 companies as of 2026-11-06
Gross margin30.1%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
Operating margin18.8%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
Net margin16.0%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
Free cash flow margin11.5%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
Price
50.8xcheaper is higher, placed against 4,362 companies as of 2026-11-06
Price to earnings50.8x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
- Computed from the filing for 2026
Price to book5.0x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
- Computed from the filing for 2026
- computed
- Computed from the filing for 2026
EV to EBITDA25.6x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
Price to sales ratio8.1x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
- Computed from the filing for 2026
- Computed from the filing for 2026
Safety
0.03safer is higher, placed against 1,436 companies as of 2026-11-06
Debt to equity0.03
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
Current ratio4.68
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
Interest coverage36.2x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
Altman Z-Scoren/a
We do not hold this figure for this company, so there is nothing to place.
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
What it pays out
0.6%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-06
Dividend yield0.6%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
Payout ratio28.9%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
Dividend cover ratio2.5x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- INR
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.